Drug details

YESCARTA (axicabtagene ciloleucel suspension for intravenous infusion)

type of CAR-T Cell Therapies

Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fever,
• easy bruising,
• unusual bleeding,
• pale skin,
• lightheadedness,
• confusion,
• chills,
• tiredness,
• dizziness,
• seizure,
• flu-like symptoms,
• weakness,
• headaches,
• mouth sores,
• anxiety,
• trouble sleeping,
• unusual thoughts or behavior,
• skin sores,
• tremors,
• shortness of breath
• problems with speech,
• cold hands and feet, and
• fast or irregular heartbeats,
• trouble speaking or understanding what is said to you,
• problems with thinking or memory,
• severe vomiting or diarrhea,

The following drugs are related to YESCARTA, either as a replacement or used together:

• Imuran (azathioprine)
• Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
• Zinecard (dexrazoxane)
• Enbrel (etanercept)
• Epkinly (epcoritamab-bysp injection)
• Remicade (infliximab)
• Lunsumio (mosunetuzumab-axgb injection)
• Purinethol (mercaptopurine)
• Oxsoralen-Ultra (methoxsalen capsules)
• Riabni (rituximab-arrx injection)
• Truxima (rituximab-abbs injection)